FULC · Insider Trading
Fulcrum Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by FULC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-20 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy | +335,232 | +$1.19M |
| 2026-07-15 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy | +499,892 | +$1.78M |
| 2026-07-02 | Kate Haviland | Director | A | +32,000 deriv. | — |
| 2026-07-02 | James A Geraghty | Director | A | +32,000 deriv. | — |
| 2026-07-02 | Colin Hill | Director | A | +32,000 deriv. | — |
| 2026-07-02 | Alan Ezekowitz | Director | A | +32,000 deriv. | — |
| 2026-07-02 | Robert J Gould | Director | A | +32,000 deriv. | — |
| 2026-07-02 | Rachel K. King | Director | A | +32,000 deriv. | — |
| 2026-07-02 | Katina Dorton | Director | A | +32,000 deriv. | — |
| 2026-07-02 | Sonja Banks | Director | A | +32,000 deriv. | — |
| 2026-05-01 | Joshua Lehrer-Graiwer | Director | A | +64,000 deriv. | — |
| 2026-02-04 | Robert J Gould | Director | Sell | −15,000 | −$160.86K |
| 2026-02-04 | Curtis Gale Oltmans | Chief Legal Officer | A | +170,000 deriv. | — |
| 2026-02-04 | Alex Sapir | See Remarks | A | +650,000 deriv. | — |
| 2026-02-04 | Greg Tourangeau | Principal Accounting Officer | A | +57,000 deriv. | — |
| 2026-02-04 | Alan A Musso | Chief Financial Officer | A | +170,000 deriv. | — |
| 2026-02-04 | Robert J Gould | Director | Sell | −15,000 | −$163.09K |
| 2026-01-06 | Robert J Gould | Director | Sell | −15,000 | −$178.09K |
| 2025-12-17 | Curtis Gale Oltmans | Chief Legal Officer | Sell | −3,452 | −$44.60K |
| 2025-12-10 | Rajeev M. Shah | 10%+ Owner | Sell | −16,700,556 | −$233.51M |
| 2025-11-21 | Robert J Gould | Director | Sell | −15,000 | −$165.50K |
| 2025-06-30 | Kate Haviland | Director | A | +36,000 deriv. | — |
| 2025-06-30 | Alan Ezekowitz | Director | A | +36,000 deriv. | — |
| 2025-06-30 | Robert J Gould | Director | A | +36,000 deriv. | — |
| 2025-06-30 | Katina Dorton | Director | A | +36,000 deriv. | — |
| 2025-06-30 | Rachel K. King | Director | A | +36,000 deriv. | — |
| 2025-06-30 | James A Geraghty | Director | A | +36,000 deriv. | — |
| 2025-06-30 | Colin Hill | Director | A | +36,000 deriv. | — |
| 2025-06-30 | Sonja Banks | Director | A | +36,000 deriv. | — |
| 2025-05-09 | Greg Tourangeau | Principal Accounting Officer | Sell | −498 | −$2.52K |
| 2025-01-28 | Curtis Gale Oltmans | Chief Legal Officer | A | +225,000 deriv. | — |
| 2025-01-28 | Alan A Musso | Chief Financial Officer | A | +285,000 deriv. | — |
| 2025-01-28 | Greg Tourangeau | Principal Accounting Officer | A | +76,120 deriv. | — |
| 2025-01-28 | Alex Sapir | See Remarks | A | +582,000 deriv. | — |
| 2024-11-14 | Rachel K. King | Director | A | +60,000 deriv. | — |
| 2024-08-23 | RA Capital Healthcare Fund LP | 10%+ Owner | J | −34,000,000 | — |
| 2024-07-08 | Alex Sapir | See Remarks | M | +150,000 | +$490.50K |
| 2024-06-18 | Katina Dorton | Director | A | +30,000 deriv. | — |
| 2024-06-18 | James A Geraghty | Director | A | +30,000 deriv. | — |
| 2024-06-18 | Kate Haviland | Director | A | +30,000 deriv. | — |
| 2024-06-18 | Robert J Gould | Director | A | +30,000 deriv. | — |
| 2024-06-18 | Colin Hill | Director | A | +60,000 deriv. | — |
| 2024-06-18 | Alan Ezekowitz | Director | A | +30,000 deriv. | — |
| 2024-06-18 | Sonja Banks | Director | A | +30,000 deriv. | — |
| 2024-06-18 | James J. Collins | Director | A | +30,000 deriv. | — |
| 2024-05-09 | Greg Tourangeau | Principal Accounting Officer | Sell | −236 | −$1.83K |
| 2024-03-20 | Patrick Taylor Horn | Chief Medical Officer | A | +400,000 deriv. | — |
| 2024-03-08 | Greg Tourangeau | Vice President, Finance | Sell | −4,884 | −$57.22K |
| 2024-03-05 | Alex Sapir | See Remarks | Buy | +43,360 | +$492.03K |
| 2024-01-30 | Curtis Gale Oltmans | Chief Legal Officer | A | +150,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rajeev M. Shah | 10%+ Owner | 8,852,079 | $32.84M |
| TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | 7,030,000 | $26.08M |
| Robert J Gould | Director | 469,864 | $1.74M |
| Alex Sapir | See Remarks | 193,360 | $717.37K |
| James A Geraghty | Director | 90,714 | $336.55K |
| Greg Tourangeau | Principal Accounting Officer | 14,062 | $52.17K |
| Curtis Gale Oltmans | Chief Legal Officer | 10,252 | $38.03K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FULC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.